Transcription of JCOG1407 - トップページ：日本臨床腫瘍研究 ...
1 Japan Clinical Oncology Group 29-A-3 JCOG1407 modified folfirinox + II ver. Randomized phase II study of modified folfirinox versus gemcitabine plus nab-paclitaxel combination therapy for locally advanced pancreatic cancer LAPC-mFOLFIRINOX/GnP-rP2 181-8611 6- 20-2 411-8777 1007 104-0045 3-8-31 2014 12 20 JCOG PC1407 2016 4 29 JCOG 2019 11 22 ver.
2 JCOG 2020 1 23 JCOG 1407 2/104 0. 29 16 JCOG modified folfirinox + II mFOLFIRINOX + II modified folfirinox mFOLFIRINOX GEM+nab-PTX Primary endpoint 1 Secondary endpoints CA19-9 dose intensity / /Grade 4
3 1 *1 *1 class IV V 2 CT CT M0 3 CT UICC-TNM 7 a) T4 b) T3 *2 1 *2 4 CT CT 5 6 20 75 7 Performance status PS ECOG 0 1 PS CA19-9 , M0, PS 0-1, 20 75 B : GEM nab-PTX nab-PTX125 mg/m2, day1,8,15 GEM1,000 mg/m2, day 1,8,154 A.
4 MFOLFIRINOX L-OHP85 mg/m2,day1l-LV200 mg/m2, day 1 Irinotecan150 mg/m2,day15-FU 2,400 mg/m2, day1-32 JCOG 1407 3/104 8 9 10 *3 *3 11 12 2 UGT1A1*6 UGT1A1*28 UGT1A1*6/*6 UGT1A1*28/*28 UGT1A1*6/*28 13 7 1 10,000 /mm3 2,000/mm3 g/dL 7 10 104 / mm3 g/dL mg/dL AST 100 U/L ALT 100 U/L mg/dL 14 A mFOLFIRINOX 2 1 L-OHP 85 mg/m2 day 1 l-LV 200 mg/m2 day 1 150 mg/m2 day 1 5-FU 2,400 mg/m2 day 1-3 B GEM+nab-PTX 4 1 nab-PTX 125 mg/m2 day 1 8 15 GEM 1,000 mg/m2 day 1 8 15 124 2 1 ver.
5 124 3 9 2 1 6 9 2016 7 13 2023 4 13 CRF JCOG JCOG JCOG
